Adesão à terapêutica: Osteodistrofia Renal
Autor(a) principal: | |
---|---|
Data de Publicação: | 2012 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/21 |
Resumo: | Medicine adherence is a qualitative indicator in health systems with the aim of providing a safe and effective care; it is particularly relevant in chronic diseases. Therapeutic strategies currently adopted for the treatment of chronic kidney disease, associated co-morbidities and complications often involve the use of a large number of drugs which affects the patient’s adherence. In fact, the compliance failures in this pathology lead to increased hospitalizations, adverse reactions and progression of the illness. Therefore, evaluation and implementation of strategies for promoting adherence are essential. Pharmacist has a key role in promoting adherence through counseling, behavioral intervention, among other interventions that have being proven effective. In this article we propose an intervention model in renal osteodystrophy in chronic kidney patients in hemodialysis. It ́s a two steps model: evaluation of adherence and intervention of a multidisciplinary team (doctor, pharmacist, nurse, dietitian and social worker) to assess and promote compliance and afterwards follow-up to evaluate the strategy. The target population is chronic kidney disease patients on hemodialysis, with dialysis sessions and on therapy for renal osteodystrophy for more than 6 months and have analytical parameters not controlled. The implementations of a questionnaire/interview allow the assessment of variables (socio-demographic, family-related, with health services and knowledge about the disease, clinical). The methodology to assess adherence proposed is the adaptation of the simplified scale to detect adherence problems. Knowledge of factors allows outlining a program to promoting adherence on non-adherent patients in different levels with interventions recorded in form. The proactive intervention of the pharmacist in chronic kidney patients will lead to a decrease on number of hospitalizations and number of administered drugs, promoting the appropriate use of drugs by the patient and improving clinical outcomes. |
id |
RCAP_bb2f99333127d32c1aa25197fc96ffb9 |
---|---|
oai_identifier_str |
oai:ojs.actafarmaceuticaportuguesa.com:article/21 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Adesão à terapêutica: Osteodistrofia RenalAdesão à terapêutica: Osteodistrofia Renaltherapeutic compliancerenal osteodystrophypharmaceutical interventionhemodialysischronic kidney disease.adesão terapêuticaosteodistrofia renalintervenção farmacêuticahemodiálisedoença renal crónicaMedicine adherence is a qualitative indicator in health systems with the aim of providing a safe and effective care; it is particularly relevant in chronic diseases. Therapeutic strategies currently adopted for the treatment of chronic kidney disease, associated co-morbidities and complications often involve the use of a large number of drugs which affects the patient’s adherence. In fact, the compliance failures in this pathology lead to increased hospitalizations, adverse reactions and progression of the illness. Therefore, evaluation and implementation of strategies for promoting adherence are essential. Pharmacist has a key role in promoting adherence through counseling, behavioral intervention, among other interventions that have being proven effective. In this article we propose an intervention model in renal osteodystrophy in chronic kidney patients in hemodialysis. It ́s a two steps model: evaluation of adherence and intervention of a multidisciplinary team (doctor, pharmacist, nurse, dietitian and social worker) to assess and promote compliance and afterwards follow-up to evaluate the strategy. The target population is chronic kidney disease patients on hemodialysis, with dialysis sessions and on therapy for renal osteodystrophy for more than 6 months and have analytical parameters not controlled. The implementations of a questionnaire/interview allow the assessment of variables (socio-demographic, family-related, with health services and knowledge about the disease, clinical). The methodology to assess adherence proposed is the adaptation of the simplified scale to detect adherence problems. Knowledge of factors allows outlining a program to promoting adherence on non-adherent patients in different levels with interventions recorded in form. The proactive intervention of the pharmacist in chronic kidney patients will lead to a decrease on number of hospitalizations and number of administered drugs, promoting the appropriate use of drugs by the patient and improving clinical outcomes. A adesão à terapêutica é um indicador de qualidade nos sistemas de saúde particularmente relevante na doença crónica. As estratégias terapêuticas actualmente instituídas para o tratamento da doença renal crónica, comorbilidades e complicações associadas implicam frequentemente o uso de um elevado número de medicamentos, condicionando a adesão do doente, e conduzindo ao aumento de hospitalizações, reacções adversas e progressão da doença. Desta forma, a avaliação e a implementação de estratégias são fundamentais. O farmacêutico tem um papel fundamental na promoção da adesão à terapêutica, através de aconselhamento, intervenções comportamentais, entre outras intervenções que demonstraram ser eficazes. O objectivo deste trabalho é a proposta de um modelo de intervenção na adesão à terapêutica na osteodistrofia renal em doentes insuficientes renais crónicos em hemodiálise. O modelo proposto envolve a avaliação da adesão à terapêutica e a promoção através da intervenção de uma equipa multidisciplinar (médico, farmacêutico, enfermeiro, nutricionista, assistente social) e posterior follow-up para avaliação da estratégia implementada. A população seleccionada são doentes renais crónicos em hemodiálise, com sessões e terapêutica para o tratamento da osteodistrofia renal há mais de 6 meses, e com parâmetros analíticos não controlados. Propõem a implementação de um questionário/entrevista para avaliação das variáveis (socio-demográficas, relaciona- das com a família, serviços de saúde e com o conhecimento sobre a doença, clínicas). Como metodologia de avaliação da adesão propõem a adaptação da escala simplificada para detecção de problemas de adesão terapêutica. Nos doentes não aderentes e conhecendo os factores envolvidos será delineado um programa de promoção da adesão ao regime terapêutico nos diferentes níveis, com intervenções registadas em formulário. A intervenção pró-activa do farmacêutico na doença renal crónica conduzirá à diminuição do número de hospitalizações e do número de medicamentos instituidos na terapêutica, promovendo a utilização adequada da medicação por parte do doente e a melhoria dos resultados clínicos. Acta Farmacêutica Portuguesa2012-06-30T00:00:00Zjournal articleinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://actafarmaceuticaportuguesa.com/index.php/afp/article/view/21oai:ojs.actafarmaceuticaportuguesa.com:article/21Acta Farmacêutica Portuguesa; v. 1 n. 2 (2012); 47-602182-3340reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://actafarmaceuticaportuguesa.com/index.php/afp/article/view/21https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/21/22Moura, M. J.Azevedo, A. L.info:eu-repo/semantics/openAccess2022-09-05T12:29:44Zoai:ojs.actafarmaceuticaportuguesa.com:article/21Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T14:59:52.581767Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Adesão à terapêutica: Osteodistrofia Renal Adesão à terapêutica: Osteodistrofia Renal |
title |
Adesão à terapêutica: Osteodistrofia Renal |
spellingShingle |
Adesão à terapêutica: Osteodistrofia Renal Moura, M. J. therapeutic compliance renal osteodystrophy pharmaceutical intervention hemodialysis chronic kidney disease. adesão terapêutica osteodistrofia renal intervenção farmacêutica hemodiálise doença renal crónica |
title_short |
Adesão à terapêutica: Osteodistrofia Renal |
title_full |
Adesão à terapêutica: Osteodistrofia Renal |
title_fullStr |
Adesão à terapêutica: Osteodistrofia Renal |
title_full_unstemmed |
Adesão à terapêutica: Osteodistrofia Renal |
title_sort |
Adesão à terapêutica: Osteodistrofia Renal |
author |
Moura, M. J. |
author_facet |
Moura, M. J. Azevedo, A. L. |
author_role |
author |
author2 |
Azevedo, A. L. |
author2_role |
author |
dc.contributor.author.fl_str_mv |
Moura, M. J. Azevedo, A. L. |
dc.subject.por.fl_str_mv |
therapeutic compliance renal osteodystrophy pharmaceutical intervention hemodialysis chronic kidney disease. adesão terapêutica osteodistrofia renal intervenção farmacêutica hemodiálise doença renal crónica |
topic |
therapeutic compliance renal osteodystrophy pharmaceutical intervention hemodialysis chronic kidney disease. adesão terapêutica osteodistrofia renal intervenção farmacêutica hemodiálise doença renal crónica |
description |
Medicine adherence is a qualitative indicator in health systems with the aim of providing a safe and effective care; it is particularly relevant in chronic diseases. Therapeutic strategies currently adopted for the treatment of chronic kidney disease, associated co-morbidities and complications often involve the use of a large number of drugs which affects the patient’s adherence. In fact, the compliance failures in this pathology lead to increased hospitalizations, adverse reactions and progression of the illness. Therefore, evaluation and implementation of strategies for promoting adherence are essential. Pharmacist has a key role in promoting adherence through counseling, behavioral intervention, among other interventions that have being proven effective. In this article we propose an intervention model in renal osteodystrophy in chronic kidney patients in hemodialysis. It ́s a two steps model: evaluation of adherence and intervention of a multidisciplinary team (doctor, pharmacist, nurse, dietitian and social worker) to assess and promote compliance and afterwards follow-up to evaluate the strategy. The target population is chronic kidney disease patients on hemodialysis, with dialysis sessions and on therapy for renal osteodystrophy for more than 6 months and have analytical parameters not controlled. The implementations of a questionnaire/interview allow the assessment of variables (socio-demographic, family-related, with health services and knowledge about the disease, clinical). The methodology to assess adherence proposed is the adaptation of the simplified scale to detect adherence problems. Knowledge of factors allows outlining a program to promoting adherence on non-adherent patients in different levels with interventions recorded in form. The proactive intervention of the pharmacist in chronic kidney patients will lead to a decrease on number of hospitalizations and number of administered drugs, promoting the appropriate use of drugs by the patient and improving clinical outcomes. |
publishDate |
2012 |
dc.date.none.fl_str_mv |
2012-06-30T00:00:00Z |
dc.type.driver.fl_str_mv |
journal article info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/21 oai:ojs.actafarmaceuticaportuguesa.com:article/21 |
url |
https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/21 |
identifier_str_mv |
oai:ojs.actafarmaceuticaportuguesa.com:article/21 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/21 https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/21/22 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Acta Farmacêutica Portuguesa |
publisher.none.fl_str_mv |
Acta Farmacêutica Portuguesa |
dc.source.none.fl_str_mv |
Acta Farmacêutica Portuguesa; v. 1 n. 2 (2012); 47-60 2182-3340 reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799129870982184960 |